Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Oct 11 - Oct 16
For example, niches may be created by addressing specific unmet needs in certain patient types (e.g., patients who prefer not to inject, or who failed prior lines of GLP-1s), or by addressing specific access issues (e.g., developing a lower-cost option, securing broader payer coverage)
Akhtar A, Shakir M, Ansari MS, Divya, Faizan MI, Chauhan V, et al
Improved Metabolic Health Blood pressure, cholesterol, and blood sugar often improve
The TSS pathway is active in the liver and brain
Known side effects (class effects similar to other GLP-1 medications) Gastrointestinal issues (very common): Nausea: 38-43% of participants vs 11% placebo Diarrhea: 33-35% vs 13% placebo Vomiting: 20-21% vs 0% placebo Constipation: 22-25% vs 9% placebo Decreased appetite: 18-19% vs 9% placebo These are expected with incretin-based therapies and typically improve over time as your body adjusts
US$ 21.82
US$ 26.96
US$ 28.23
US$ 26.98
US$ 23.24
US$ 27.60
